Teclistamab was found to have improved effectiveness in terms of progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) vs real-world physician’s choice of therapy in patients with triple-class exposed relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy, according to data from a recent study.1
For the research, individual patient-level data were collected from the phase 1/2 MajestTEC-1 trial (NCT04557098) and were compared with an external control arm that utilized data from patients in the nationwide de-identified electronic health record-derived Flatiron Health Multiple Myeloma cohort database.
Outcomes were assessed as time-to-event data utilizing inverse probability of treatment weighting (IPTW) adjusted Kaplan-Meier estimates and a weighted Cox proportional hazards model to estimate the hazard ratio (HR) and its 95% confidence interval (CI).
The findings from the base case analysis, which were presented during the 2022 ASCO Annual Meeting, showed that the median OS with teclistamab was 18.3 months vs 13.8 months in the unweighted Flatiron cohort and 14.6 months in the weighted flatiron cohort (unadjusted HR, 0.67; 95% CI, 0.47-0.95; best case HR, 0.73; 95% CI, 0.50-1.07; P = .1084).
Read More: https://www.onclive.com/view/teclistamab-provides-substantial-clinical-benefit-over-real-world-physician-s-choice-in-triple-class-exposed-r-r-myeloma